Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Core Insights - Kura Oncology is showcasing the potential of KO-2806 (darlifarnib) in combination with various targeted therapies to enhance anti-tumor activity and address resistance mechanisms in cancer treatment [1][2][4] Group 1: KO-2806 Development and Clinical Data - KO-2806 is a next-generation farnesyl transferase inhibitor (FTI) designed for superior potency and pharmacokinetics compared to first-generation candidates [4] - Preliminary clinical data for KO-2806 will be presented at the ESMO Congress 2025 in October [1][5] - The company is conducting ongoing Phase 1 trials for KO-2806, with a focus on its combination with standard-of-care agents [4] Group 2: Mechanisms of Action and Preclinical Findings - KO-2806 has shown robust preclinical activity by suppressing mTOR signaling, enhancing the efficacy of antiangiogenic TKIs, PI3Kα inhibitors, and KRAS inhibitors [4] - The preclinical studies indicate that KO-2806 can re-sensitize tumors in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) models to KRAS inhibitors [4] - The findings suggest broad applicability across multiple cancer types, potentially impacting over 200,000 new patients annually in the U.S. [4] Group 3: Future Events and Presentations - Kura plans a second analyst/investor event on October 18, 2025, to review clinical data from the ESMO Congress presentations [5] - The company emphasizes the importance of innovative combination therapies to overcome resistance in cancer treatment [2][4]